Top Markets
Coin of the day
Citius Oncology, Inc. Citius Oncology, Inc.

Citius Oncology, Inc.

CTOR
Rang in Aktien #23802
Citius Oncology, Inc. concentrates on advancing innovative, targeted... Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Aktienkurs
$0.7426
Zuletzt synchronisiert: 2026-08-21
Marktkapitalisierung
$69.05M
Veränderung (1 Tag)
-2.17%
Veränderung (1 Jahr)
-57.57%
Land
US
Handel Citius Oncology, Inc. (CTOR)

Kategorie

Kursverlauf für Citius Oncology, Inc. (CTOR)
Höchster Schlusskurs: $0.77 am 2026-08-01

Niedrigster Schlusskurs: $11.37 am 2024-07-01
Kursverlauf der Aktie von Citius Oncology, Inc. von 2024 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -4.49%
2025 2.60%
2024 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$1.26K 76.64%
US
$270.77 51.02%
US
$265.40 26.02%
US
$493.69 44.66%
CH
$152.42 74.45%
US